Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug

HALIFAX, NOVA SCOTIA--(Marketwired - May 16, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that an...
May 10, 2017 17:05 ET | Source: Immunovaccine Inc.

Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017

HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today released its financial and operational...
May 02, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine to Present at 19th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference

HALIFAX, NOVA SCOTIA--(Marketwired - May 2, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the company's Vice President...
April 18, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers

HALIFAX, NOVA SCOTIA--(Marketwired - April 18, 2017) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company,...
April 12, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate

HALIFAX, NOVA SCOTIA--(Marketwired - April 12, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced updated data on its...
April 11, 2017 07:05 ET | Source: Immunovaccine Inc.

Princess Margaret Cancer Center Receives Health Canada Clearance to Begin Investigator-Sponsored Phase 2 Ovarian Cancer Study Evaluating Immunovaccine's DPX-Survivac with Merck's Pembrolizumab

HALIFAX, NOVA SCOTIA--(Marketwired - April 11, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that University Health Network's...
April 07, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference

HALIFAX, NOVA SCOTIA--(Marketwired - April 7, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic...
April 05, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy

HALIFAX, NOVA SCOTIA--(Marketwired - April 5, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that new preclinical data presented at...
March 30, 2017 17:05 ET | Source: Immunovaccine Inc.

Immunovaccine Announces 2016 Year-End Results

HALIFAX, NOVA SCOTIA--(Marketwired - March 30, 2017) - Immunovaccine Inc. ("Immunovaccine" or the "Corporation") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy...
March 29, 2017 07:05 ET | Source: Immunovaccine Inc.

Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat

HALIFAX, NOVA SCOTIA--(Marketwired - March 29, 2017) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company,...